The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary.
 
Gauri R. Varadhachary
Employment - Fannin Partners (I)
Leadership - Fannin Partners (I); Pulmotect (I)
Stock and Other Ownership Interests - Fannin Partners (I)
Honoraria - Celgene; Merrimack; Momenta Pharmaceuticals; Rexahn Pharmaceuticals
Consulting or Advisory Role - Celgene; Merrimack; Momenta Pharmaceuticals; Rexahn Pharmaceuticals
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - Spouse is an inventor of use patents relating to recombinant human lactoferrin. The molecule is no longer in development and patents are being allowed to lapse as payments come due. (I); Spouse is inventor on a pending patent for an ELISA diagnostic platform. Not related to my area of research. (I)
Travel, Accommodations, Expenses - Celgene and Merrimack
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - Genentech (Inst)
 
Shubham Pant
Consulting or Advisory Role - Celgene; Halozyme
 
Filip Janku
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; Novartis; Sequenom; Trovagene
Research Funding - Agios; Astellas Pharma; Biocartis; BioMed Valley Discoveries; Deciphera; Foundation Medicine; Fujifilm; Novartis; Piqur; Plexxikon; Roche; Symphony Evolution; Trovagene
Other Relationship - Bio-Rad
 
Siqing Fu
No Relationships to Disclose
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Sarina Anne Piha-Paul
No Relationships to Disclose
 
Rivka R. Colen
No Relationships to Disclose
 
Vivek Subbiah
Research Funding - Novartis, GSK, Nanocarrier, NorthWest Biotherapeutics, Roche/Genentech, BergPharma, Bayer, Incyte, FujiFilm, Pharmamar, D3, Pfizer Amgen, Abbvie, Multivir, Bluprint Medicines.
Travel, Accommodations, Expenses - Novartis, Pharmamar, Fujifilm
 
Jeane Painter
No Relationships to Disclose
 
Apostolia Maria Tsimberidou
Research Funding - Baxter (Inst); Bayer (Inst); EMD Serono (Inst); Foundation Medicine (Inst); ONYX (Inst)
 
Bettzy Stephen
No Relationships to Disclose
 
Daniel D. Karp
No Relationships to Disclose
 
Lacey McQuinn
No Relationships to Disclose
 
Tito R. Mendoza
No Relationships to Disclose
 
Kenneth R. Hess
Travel, Accommodations, Expenses - Angiochem
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks
 
Aung Naing
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Baxter (I); EMD Serono; Healios; Incyte; Karyopharm Therapeutics; MedImmune; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences